TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06653894

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patients undergoing hip replacement surgery
Description: Hip surgery typically involves procedures aimed at repairing or replacing damaged hip joints to alleviate pain and restore mobility. Common types of hip surgery include total hip replacement, partial hip replacement, and hip arthroscopy. Total hip replacement involves removing the damaged joint and replacing it with an artificial implant, while partial hip replacement focuses on replacing only the damaged parts of the joint. Hip arthroscopy is a minimally invasive procedure used to diagnose and treat hip joint issues using small incisions and specialized instruments. Recovery from hip surgery can vary, but many patients experience significant improvement in pain levels and mobility with proper rehabilitation and physical therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patients undergoing hip replacement surgery
Description: Hip surgery typically involves procedures aimed at repairing or replacing damaged hip joints to alleviate pain and restore mobility. Common types of hip surgery include total hip replacement, partial hip replacement, and hip arthroscopy. Total hip replacement involves removing the damaged joint and replacing it with an artificial implant, while partial hip replacement focuses on replacing only the damaged parts of the joint. Hip arthroscopy is a minimally invasive procedure used to diagnose and treat hip joint issues using small incisions and specialized instruments. Recovery from hip surgery can vary, but many patients experience significant improvement in pain levels and mobility with proper rehabilitation and physical therapy.
Study: NCT06662643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed transanal pull-through anastomosis
Description: Laparoscopic surgery is recommended. A standard 5-port method is used to create pneumoperitoneum after placing the trocar. The sigmoid colon and upper rectal mesentery are dissected along Toldt's fascia. Autonomic nerves should be preserved, and high ligation of the inferior mesenteric vessels with lymph node dissection is recommended. TME: Using a posterior-to-anterior approach, the mesorectal plane is dissected down to the pelvic floor, cutting the Waldeyer's fascia to enter the intersphincteric space, where sharp dissection is carried out toward the levator ani muscle hiatus. The dissection endpoint is the dentate line, where the proximal colon is exteriorized by at least 2 cm and sutured to the anal canal with 6-8 stitches, without a protective ileostomy.Two to four weeks after the first surgery, after the colon has adhered well to the surrounding tissue, the exteriorized colon is excised (under epidural or spinal anesthesia, trimming the exteriorized colon to form the anus).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Anastomosis Plus Prophylactic Ileostomy
Description: ISR is categorized into partial ISR (PISR), subtotal ISR, and total ISR (TISR). Correspondingly, the anastomosis site after coloanal anastomosis is located below the levator ani hiatus (PISR, near the dentate line; subtotal-ISR and TISR, below the dentate line).The dissection steps are the same as in the first stage of the Staged Turnbull-Cutait Pull-through Anastomosis group (TME and intersphincteric space dissection).The bowel is transected at least 1 cm below the tumor, leaving a larger segment of healthy tissue on the non-tumor side while ensuring that no more than 1/3 of the dentate line is resected to avoid impairing fecal control.Anastomosis is performed using absorbable sutures under direct visualization. A protective ileostomy is created 25-30 cm from the ileocecal valve.3 to 6 months after surgery, the ileostomy is reversed. Prior to closure, digital rectal examination, defecography, MRI, colonoscopy, and other evaluation must perform.
Study: NCT06662682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration
Description: The intervention (IC) will be specified as a five-minute Whole-Body Vibration session. The WBV take place on a side alternating vibration plate (Wellengang, Germany). The patients stand barefoot on the vibration plate on a prescribed position. In this position the amplitude will be 6-7mm. The WBV protocol contains mobilizing sequences with lower frequencies and activating sequences with higher frequencies

Intervention type: OTHER
Group type: OTHER
Intervention: Control Condition
Description: Non-intervention control condition
Study: NCT06663826

Intervention type: DIAGNOSTIC_TEST
Intervention: oculomotor and pupillary function assessment
Description: This is an exploratory open-label single-centre research project intended to collect data of PD patients in order to develop machine learning models for helping in the diagnosis and monitoring of PD. Each patient will have an initial visit and then a second visit after two weeks. The estimated duration of the study visit 1 is 3 hours, not taking into account the time for patient information and informed consent. The estimated duration of the study visit 2 is 2 hours. During these two visits, patients will undergo an MDS-UPDRS assessment, a neos examination, a standard manual ocular motor and pupil function examination, and gait assessment simultaneously with GaitQ senti and an IMU sensor placed on their back. In the two weeks separating the two visits, patient's gait will be monitored daily at home with GaitQ senti, where they will perform a daily TUG test comprising of 15 m walk, 5 sit to stand, and 5-minute walk. Healthy individuals data will be included from a previous study.

Intervention type: DIAGNOSTIC_TEST
Intervention: oculomotor and pupillary function assessment
Description: This is an exploratory open-label single-centre research project intended to collect data of PD patients in order to develop machine learning models for helping in the diagnosis and monitoring of PD. Each patient will have an initial visit and then a second visit after two weeks. The estimated duration of the study visit 1 is 3 hours, not taking into account the time for patient information and informed consent. The estimated duration of the study visit 2 is 2 hours. During these two visits, patients will undergo an MDS-UPDRS assessment, a neos examination, a standard manual ocular motor and pupil function examination, and gait assessment simultaneously with GaitQ senti and an IMU sensor placed on their back. In the two weeks separating the two visits, patient's gait will be monitored daily at home with GaitQ senti, where they will perform a daily TUG test comprising of 15 m walk, 5 sit to stand, and 5-minute walk. Healthy individuals data will be included from a previous study.
Study: NCT06664177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversalis Fascia Plane Block
Description: In the Transversalis Fascia Block group, the same procedure will be followed as in the Quadratus Lumborum block group, with the ultrasound probe being placed in the same location, and the same in-plane technique will be applied with a 22G 100 mm peripheral block needle. After hydrodissection, 20 mL of 0.5% bupivacaine will be injected slowly in the same manner.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block (QLB)
Description: In the Quadratus Lumborum block group, in the lateral decubitus position, a convex ultrasound probe will be sterilely placed in the subcostal area and above the iliac crest. The quadratus lumborum and psoas major muscles, as well as the L4 vertebra's transverse process, will be visualized. Using the in-plane technique and a 22G 100 mm peripheral block needle, the placement will first be identified through hydrodissection in the subfascial area between the quadratus lumborum and psoas major muscles. After localization, 20 mL of 0.5% bupivacaine will be injected slowly, aspirating every 5 cc, while visualizing the local anesthetic pushing the fascia in the ultrasound image.
Study: NCT06663254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4
Description: Individualized goal-directed administration of 6% Hydroxyethyl starch (HES) 130/0.4: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min. If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. If the use of HES exceeds 30 ml/kg, sodium acetate Ringer will be replaced. In addition, patients will have a background infusion of sodium acetate Ringer's solution at 4 ml/kg/h to satisfy the maintenance fluid requirements during surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium acetate Ringer
Description: Individualized goal-directed administration of crystalloid alone: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min.~If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. In addition, patients will have a background infusion of sodium acetate, the maintenance fluid requirement during surgery.
Study: NCT06662669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-13027
Description: YL-13027 is a small molecule inhibitor of the TGF-βRI target.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-13027
Description: YL-13027 is a small molecule inhibitor of the TGF-βRI target.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY-0102
Description: HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY-0102
Description: HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis
Study: NCT05591417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilevel Erector spinae plane block
Description: Patients will receive bilevel erector spinae plane block with bupivacaine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Erector spinae plane block with dexamethasone
Description: Patients will receive bilevel erector spinae plane block with bupivacaine and dexamethasone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Erector spinae plane block with dexmedetomidine
Description: Patients will receive bilevel erector spinae plane block with bupivacaine and dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: Intravenous morphine 0.1 mg/kg
Study: NCT06601270

Intervention type: OTHER
Intervention: There are no interventions as the study is purely observational.
Description: There are no interventions as the study is purely observational.

Intervention type: OTHER
Intervention: There are no interventions as the study is purely observational.
Description: There are no interventions as the study is purely observational.
Study: NCT06444789

Intervention type: DEVICE
Intervention: connected smartwatch
Description: The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.
Study: NCT04229758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Description: DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Description: DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
Study: NCT06444789

Intervention type: DEVICE
Intervention: connected smartwatch
Description: The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.

Intervention type: DEVICE
Intervention: connected smartwatch
Description: The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.
Study: NCT06664372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans fontanelle US Guided VP Shunt
Description: Insertion of proximal VP shunt catheter by trans fontanelle US
Study: NCT04229758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Description: DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
Study: NCT06659315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Problem Solving Therapy
Description: A couples-based problem solving program to deal with depression, PMTCT adherence, and couple communication.
Study: NCT06659445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONL1204 Opthalmic solution
Description: Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONL1204 Opthalmic solution
Description: Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
Study: NCT05643625

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates exercise and myofascial release
Description: Pilates exercise and myofascial relaxation technique will be applied to the experimental group and pilates exercise will be applied to the control group.
Study: NCT06659445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONL1204 Opthalmic solution
Description: Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avacincaptad Pegol intravitreal solution
Description: Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection
Study: NCT05643625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise and myofascial release
Description: Pilates exercise and myofascial relaxation technique will be applied to the experimental group and pilates exercise will be applied to the control group.
Study: NCT06659445

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham injection
Study: NCT05759988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Outpatient Foley catheter
Description: Outpatient Foley catheter placement for induction of labor
Study: NCT04798027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine formulation 1
Description: Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine formulation 1
Description: Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine formulation 1
Description: Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine formulation 2
Description: Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine formulation 2
Description: Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine formulation 2
Description: Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine formulation 3
Description: Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% normal saline)
Description: Pharmaceutical form: Liquid Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% normal saline)
Description: Pharmaceutical form: Liquid Route of administration: Intramuscular injection
Study: NCT04376918

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Begin with BVGA
Description: Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask
Study: NCT05943860

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pantovigar® vegan
Description: Oral application of 1 capsule three times a day (morning, noon, evening) for 6 months
Study: NCT05551364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATLAS 2030 exoskeleton
Description: Individualized Rehabilitation Treatment with the ATLAS 2030 Exoskeleton consists of the following phases:~1. Telephone contact phase (1 session)~2. Inclusion Phase (1 session)~3. Signing of informed consent (1 session)~4. Initial Evaluation Phase (1 session)~5. Treatment Phase (1st part) (7 sessions)~6. Monthly Evaluation Phase (1 session)~7. Treatment Phase (2nd part) (7 sessions)~8. Monthly Evaluation Phase (1 session)~9. Treatment Phase (3rd part) (7 sessions)~10. Final Evaluation Phase and results (2 sessions)
Study: NCT04376918

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Begin with Face-mask
Description: Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask
Study: NCT06033183

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample collection : 2 X 5 ml
Study: NCT05754749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol 350 Mg/mL Injectable Solution
Description: Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. Images will be acquired of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.
Study: NCT05007106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab Co-Formulation
Description: Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab Co-Formulation
Description: Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab Co-Formulation
Description: Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab Co-Formulation
Description: Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
Study: NCT04943016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 Chimeric Antigen Receptor (CAR) T Cells
Description: This study seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children and adults with relapsed/refractory B cell malignancies. The overall goal of this study is to validate the safety profile of administration CD19 CAR T cells and describe the toxicities in children and adults with relapsed/ refractory B cell malignancies. Each patient implements leukapheresis 2 weeks after enrollment and infuse CD19 CAR-T cell around 2 weeks after leukapheresis, and administrated chemotherapy lymphodepletion regimen 1 week before infusion. Furthermore, the treated subject would be following up around 2 years.
Study: NCT05412550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise self-management
Description: Six walking exercise self-management telehealth sessions will focus on behavior change techniques and personalized action plans. Peer support groups will be held every three months, and will be focused on supporting participants in attaining sustained exercise. Text message prompts will focus on encouraging exercise and health self-management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: The six individual telehealth sessions, six peer-group sessions, and text message prompts will focus on general health education. No prompts for exercise or health self-management will be given.
Study: NCT04857866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb27564
Description: Single ascending dose of XmAb27564

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo
Study: NCT05066841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)
Description: CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)
Description: 10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) and 90% starch for 12 weeks